Abstract
There is now a plethora of different imaging techniques used for diagnosing and treating brain tumours. Different contrast agents in magnetic resonance imaging – coupled with amino acid tracers used in positron emission tomography – are the new weapons in radiologists’ armoury which allow them to target and measure tumours more accurately. Brain tumours are among the top causes of tumour-related deaths, with ten to 15 out of every 100,000 people diagnosed in Europe and USA every year. The evaluation of tumours with medical imaging modalities is now one of the primary concerns of radiology departments. Computed tomography (CT), magnetic resonance imaging (MRI) and various advanced MRI techniques like perfusion MRI and dynamic susceptibility contrast (DSC) MRI play a vital role in brain tumour assessment. In this chapter, we will summarize the current clinical applications of Computed Tomography, gadolinium contrast agents in neuro-imaging, including contrast-enhanced MRI, perfusion-weighted imaging and positron emission tomography (PET) for evaluation of brain tumour lesions. We will also discuss the advantages and limitation of each modality with respect to answering the specific clinical concerns.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
